Drug-resistant Tuberculosis Treatment Market Trends

Growth Drivers

• Government introducing encouraging policies to increase diagnostics demand - To reduce the burden of TB disease across the world, the government has introduced various policies. People are becoming more aware of the dreadfulness of this disease. The majority of the countries are now focusing on the policies developed by the government to increase the diagnosis rate of this disease.
  
  As per the latest report by WHO, around 79% of the funding used for the prevention, diagnosis, and treatment of TB comes from domestic sources. From 2019 to 2021, spending from domestic sources has declined (USD 0.66 billion), and spending from sources from international donors (USD 0.06 billion) has increased. 

• Discovery of new drugs to treat drug-resistant TB - The development of new drugs can resist the increasing drug-resistant tuberculosis. Various innovative medications such as bedaquiline and delamanid provide effective results and a safer approach for treating severe TB cases.
  
  Moreover, there has been tremendous support from the key players of the market for the development of new anti-tuberculosis drugs. The increasing chronic disease management requires developing cutting-edge medications, thereby inducing growth in the market.
  
  Additionally, tuberculosis eradication is among one of the sustainable development goals which is yet to be achieved by 2030. According to WHO, the Stop TB Partnership’s Global Plan to End TB, 2018–2022 (the Global Plan) has estimated that around USD 9.2 billion was needed for the prevention of TB, diagnostics and treatment services in 128 LMICs (Low- and middle-income countries) in 2018, rising to USD 15.6 billion in 2021 and USD 16.1 billion in 2022. It was expected that an additional USD 2 billion per year was required for TB research.

Challenges

• Difficulty in diagnosis of drug-resistant TB in early stages - When the TB is not diagnosed at an early stage, the resistant strain keeps spreading. Therefore, an early diagnosis is crucial for stopping the further prevalence and offering treatment as per the patient’s condition.

• Limited availability of resources for testing - Unavailability and limitations of testing antibiotics and the high cost of medications are the primary issues faced by a TB patient. Moreover, many hospitals and pharmacies have no access to drug-resistant treatment.